Table 1.

Clinical trials using BMMNCs and PBMNCs for CLI patients

Author	Year	Cell type	Target disease	Delivery	Study population	Outcome	Follow-up	References
Esato et al.	2002	BMMNC	CLI	IM	8	↑Symptom, ↑thermography, complete ulcer healing; 2/3 (67%) major amputation rates; 0	Not determined	[20]
Tateishi-Yuyama et al.	2002	BMMNC and PBMNC	CLI	IM	45	↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; 6/10 (60%) major amputation rates; not shown	4 and 24 weeks	[25]
Huang et al.	2005	PBMNC	CLI	IM	28	↑Symptom, ↑ABI, ↑LDP, complete ulcer healing; 14/18 (78%) major amputation rates; 0	3 months	[88]
Lenk et al.	2005	PBMNC	CLI	IA	7	↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; not shown major amputation rates; 0	20 weeks	[89]
Miyamoto et al.	2006	BMMNC	CLI	IM	8	↑Symptom, no ∆ ABI, complete ulcer healing; 7/8 (88%) major amputation rates; 0	684 days	[81]
Durdu et al.	2006	BMMNC	CLI	IM	28	↑Symptom, ↑ABI, ↑LDP, complete ulcer healing; 15/18 (83%) major amputation rates; 0	16.6 months	[79]
Arai et al.	2006	BMMNC	CLI	IM	39	↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; 3/8 (38%) major amputation rates; not shown	1 months	[90]
Kawamoto et al.	2009	PBMNC (CD34+)	CLI	IM	17	↑Symptom, ↑TBI, ↑TcPO2, no ∆ ABI, complete ulcer healing; not shown major amputation rates; 0	3 months	[91]
Prochazka et al.	2010	BMC	CLI	IM	96	↑Symptom, ↑ABI, ↑LDP, ↑SPP, no ∆ TcPO2, complete ulcer healing; 33/42 (79%) major amputation rates; 9/42 (21%)	4 months	[92]
Murphy et al.	2011	BMMNC	CLI	IM	29	↑Symptom, ↑FTP, ↑TBI, complete ulcer healing; 3/9 (33%) major amputation rates; 4/29 (14%)	12 months	[93]
Walter et al.	2011	BMMNC	CLI	IA	40	↑Symptom, no ∆ ABI, no ∆ TcPO2, complete ulcer healing; 3/15 (20%) major amputation rates; 3/19 (16%)	3 months	[78]
Losordo et al.	2012	PBMNC (CD34+)	CLI	IM	28	No ∆ symptom, no ∆ ABI, no ∆ TBI, complete ulcer healing; 2/5 (40%) major amputation rates; 5/16 (31%)	12 months	[94]
Tanaka et al.	2014	PBMNC (CD34+)	CLI	IM	5	↑Symptom, ↑SPP, ↑TcPO2, no ∆ ABI, complete ulcer healing; 2/5 (40%) major amputation rates; 0	5 months	[95]
Teraa et al.	2015	BMMNC	CLI	IA	160	↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; 19/51 (37%) major amputation rates; 21/81 (26%)	9 months	[96]

BMMNC bone marrow derived mononuclear cell, PBMNC peripheral blood mononuclear cell, BMC bone marrow cell, CLI critical limb ischemia, IM intramuscular, IA intraarterial, ↑ improved, ∆ change, ABI ankle brachial pressure index, TcPO ₂ transcutaneous oxygen pressure, SPP skin perfusion pressure, LDP laser Doppler perfusion, TBI toe brachial pressure index, FTP first toe pressure